Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

NCT06389682 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma Metastatic

Interventions

DRUG: 68Ga-NYM005 injection

Sponsor

Norroy Bioscience Co., LTD